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Neocortical neuronsTruncating or missense mutation of cullin 4B (CUL4B) is one of the most prevalent causes underlying
X-linked intellectual disability (XLID). CUL4B-RING E3 ubiquitin ligase promotes ubiquitination and degrada-
tion of various proteins. Consistent with previous studies, overexpression of wild-type CUL4B in 293 cells en-
hanced ubiquitylation and degradation of TSC2 or cyclin E. The present study shows that XLID mutant
(R388X), (R572C) or (V745A) CULB failed to promote ubiquitination and degradation of TSC2 or cyclin
E. Adenoviruses-mediated expression of wild-type CUL4B decreased protein level of TSC2 or cyclin E in cul-
tured neocortical neurons of frontal lobe. Furthermore, shRNA-mediated CUL4B knockdown caused an
upregulation of TSC2 or cyclin E. XLID mutant (R388X), (R572C) or (V745A) CUL4B did not downregulate
protein expression of TSC2 or cyclin E in neocortical neurons. By promoting TSC2 degradation, CUL4B could
positively regulate mTOR activity in neocortical neurons of frontal cortex. Consistent with this hypothesis,
CUL4B knockdown-induced upregulation of TSC2 in neocortical neurons resulted in a decreased protein level
of active phospho-mTORSer2448 and a reduced expression of active phospho-p70S6KThr389 and phospho-
4E-BP1Thr37/46, two main substrates of mTOR-mediated phosphorylation. Wild-type CUL4B also increased
protein level of active phospho-mTORSer2448, phospho-p70S6KThr389 or phospho-4E-BP1Thr37/46. XLID CUL4B
mutants did not affect protein level of active phospho-mTORSer2448, phospho-p70S6KThr389 or phospho-
4E-BP1Thr37/46. Our results suggest that XLID CUL4B mutants are defective in promoting TSC2 degradation and
positively regulating mTOR signaling in neocortical neurons.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Intellectual disability (ID) is found in ~1%–2% of the human popu-
lation and is more prevalent in males than in females [1–3]. The etiol-
ogy of intellectual disability (ID) is heterogeneous, and the most
prevalent cause is the mutations at various loci of the X chromosome
[1–4]. Up to now, mutations of 102 genes of the X chromosome have
been shown to be associated with X-linked intellectual disability
(XLID) [5]. Based on the presence or absence of other symptoms,
XLID can be divided into syndromic and nonsyndromic forms [1–4].
Previous molecular genetic studies demonstrated that truncating or
missense mutations of cullin 4B (CUL4B) gene located on the Xq24
locus were observed in male ID patients with other CNS syndromes,
including relative macrocephaly, unprovoked aggressive outbursts
and intention tremor [6–10]. CUL4B mutation is one of the most fre-
quently mutated genes underlying XLID [6–10]. XLID truncating orhang Gung University School of
3 211 8800x5060; fax: +886 3
).
rights reserved.missense mutations of CUL4B are believed to cause the impaired
CUL4B function in the brain and resulting intellectual disability
[6,7]. However, further studies are required to investigate the func-
tional consequence of XLID mutations on CUL4B-mediated physiolog-
ical effects and molecular pathogenic mechanisms underlying XLID
mutant CUL4B-induced intellectual disability in the brain.
Over 1000 distinct E3 ligases, which belong to either the HECT fam-
ily or the RING family, are found in eukaryotic cells [11,12]. Cullin 4B is a
member of family of seven mammalian cullins (cullin 1, 2, 3, 4A, 4B, 5
and 7), which bind to a small RING protein ROC1 or ROC2 (for RING of
cullins) and form the largest class of E3 ligases, the cullin-RING E3 li-
gases [11–13]. In contrast to RING E3 ligases that bind substrates direct-
ly, the cullin-RING E3 ligase complex does not interact with substrate
directly. Instead, cullin-mediated ubiquitination requires substrate
recruiting receptors that are typically joined to cullin-RING E3 ligase
complex by a linker protein [11–13]. The C-terminal domain of CUL4B
binds to ROC1 or ROC2, which recruits and allosterically activates an
E2 enzyme that transfers ubiquitin to the substrate, and assembles
into a CUL4B-RING E3 ubiquitin ligase (CRL4B). N-terminal domain of
CUL4B interacts with DDB1 (damaged DNA binding protein 1), which
acts as the linker protein and links CRL4B to a family of DWD
(DDB1-binding WD40) proteins that function as substrate receptors
586 H.-L. Wang et al. / Biochimica et Biophysica Acta 1832 (2013) 585–593and recruit different substrates to CUL4B-ROC-E2 catalytic core.
CUL4B-RING E3 ubiquitin ligase has been shown to cause ubiquitylation
and subsequent 26S proteasome-mediate degradation of several
proteins, which are implicated in DNA replication, cell cycle control,
chromatin formation, DNA damage repair, signal transduction and de-
velopment [12].
In mammalian cells, Ser/Thr protein kinase mTOR (mammalian tar-
get of rapamycin) functions as the essential component of two distinct
multi-protein signaling complexes called mTORC1 and mTORC2 [14].
The rapamycin-sensitive mTORC1 regulates various intracellular pro-
cesses, including translation, autophagy, cell cycle and microtubule
dynamics [14,15]. Kinase activity of mTOR is controlled by various
stimuli such as trophic factors, hormones, neurotransmitters, amino
acids, cell energy status and cellular stress [14]. Activation of receptor ty-
rosine kinases or neurotransmitter receptors leads to the activation of
phosphatidyl-inosital-3 kinase (PI3K), and activated PI3K promotes
the formation of phosphatidylinositol-3,4,5-trisphospate (PIP3). An in-
creased level of PIP3 causes the recruitment of phosphoinositide-
dependent kinase 1 (PDK1) and AKT/protein kinase B (PKB) to the cell
membrane and subsequent phosphorylation of AKT by PDK1. Active
phospho-AKT activatesmTORC1 by phosphorylating a GTPase activating
protein TSC2/tuberin, which forms the tuberous sclerosis complex (TSC)
with TSC1/hamartin [16]. TSC1/TSC2 complex negatively regulates
mTORC1 signaling by inhibiting the Rheb (Ras homolog enriched in
brain) GTPase, a positive regulator of mTORC1. AKT phosphorylation of
TSC2 inhibits activity of TSC1/TSC2 complex, which allows GTP-bound
Rheb to accumulate and activate the mTOR of mTORC1. Then, active
and phospho-mTOR of mTORC1 acts primarily by phosphorylating
4E-BP (eukaryotic translation initiation factor 4E binding protein) and
p70 ribosomal S6 protein kinase (p70S6K), which are two main regula-
tors of mRNA translation and ribosome biogenesis [14,15]. In the brain,
mTOR signaling regulates survival, differentiation and development of
neurons [14]. Proper mTOR activity is required for axon guidance, den-
drite development, dendritic spine morphogenesis and synaptogenesis
[14,17]. The mTOR signaling cascade also mediates long-term synaptic
plasticity including late long-term potentiation (LTP) or mGluR-
dependent long-term depression (LTD), which underlies processes of
learning and memory formation [18–21]. Long-lasting synaptic plastic-
ity andmemory require new protein synthesis [18,19]. Previous studies
reported that late LTP- or mGluR-LTD-inducing stimulation induced
mTOR-mediated phosphorylation of downstream targets, 4E-BP and
p70S6K, and subsequent activation of translation machinery in the
dendrites [18–20,22,23]. Therefore, dysregulation ofmTOR signaling ac-
tivity is believed to be one of molecular pathogenic mechanisms under-
lying intellectual disability [21].
Previous study using cell lines demonstrated that CUL4-DDB1
ubiquitin E3 ligase regulates mTOR activity through promoting the
degradation of an inhibitor of mTOR signaling by ubiquitin-dependent
proteolysis [24]. Interestingly, TSC2, a negative regulator ofmTOR activ-
ity, in HEK 293 or U2OS cells has been shown to be recruited by a DWD
protein FBW5 to CUL4B-ROC1 E3 ubiquitin ligase, resulting in the sub-
sequent polyubiquitination and degradation of TSC2 [25]. A recent
study [26] and our unpublished RT-PCR assays indicated that CUL4B
mRNA and protein are highly expressed in various regions of the
mouse brain including the cerebral cortex, cerebellum and hippocam-
pus. Therefore, it is possible that CUL4B positively regulates mTOR sig-
naling activity of cerebral cortex, which plays an essential role in
controlling long-term synaptic plasticity and learning and memory
function, via promoting the removal of TSC2. XLIDmutant CUL4B is like-
ly to lose the ability to cause the ubiquitination anddegradation of TSC2,
leading to the dysregulated mTOR signaling activity in neocortical neu-
rons and resulting intellectual disability. In the present study, our re-
sults indicate that XLID truncating or missense mutations impair the
ability of CUL4B to promote ubiquitylation and degradation of TSC2
and that XLID CUL4B mutants are defective in positively regulating
mTOR activity in neocortical neurons.2. Materials and methods
2.1. Construction of point mutant or truncated CUL4B
Inﬂuenza hemagglutinin epitope (HA, YPYDVPDYA) was added to
the C-terminus of human wild-type CUL4B by performing PCR ampli-
ﬁcation. According to our previous study [27], oligonucleotide-
directed mutagenesis using PCR ampliﬁcation was performed to pre-
pare cDNA encoding XLID mutant (R572C) or (V745A) CUL4B [6].
HA-tagged cDNA of XLID truncated (R388X) CUL4B [6,7] was obtained
by performing PCR ampliﬁcation using the full-length cDNA of CUL4B
as the template. DNA mutations of CUL4B were conﬁrmed by
performing dideoxy DNA sequencing.2.2. Stable expression of wild-type or XLID mutant CUL4B in HEK 293
cells
The cDNA of HA-tagged wild-type or XLID mutant CUL4B was
subcloned into a mammalian expression vector pcDNA3 (Invitrogen)
and transfected to HEK 293 cells using Lipofectamine 2000 (Invitrogen).
Two days after the transfection, 293 cells expressing wild-type, (R572C),
(V745A) or (R388X) CUL4B were selected by adding 1.5 mg/ml G418
(geneticin sulfate) to culture medium. Positive clones were conﬁrmed
by performingWestern blot analysis as described below andmaintained
in the medium containing 0.5 mg/ml G418.2.3. Preparation of primary cultured neocortical neurons
Cultured neocortical neurons of frontal cortex were prepared as de-
scribed previously [28]. Brieﬂy, frontal lobe of cerebral cortex was dis-
sected from postnatal 1 day- or 2 days-old mice and incubated with
DMEM/F12 medium containing pronase (0.5 mg/ml) and DNase I
(0.3 mg/ml) for 50 min at 37 °C. Tissue fragments were then triturated,
and dissociated cells were plated onto poly-L-ornithine-coated six-well
dishes. Neocortical neurons were cultured in DMEN/F12 medium
supplemented with 5% fetal bovine serum and 5% horse serum. From
the second day in culture, proliferation of glial cells was prevented by
adding 5′-ﬂuoro-2′-deoxyuridine and uridine into the medium.2.4. Preparation of recombinant adenoviruses
AdEasy Adenoviral Vector System (Stratagene) was used to prepare
recombinant adenoviruses containing cDNA of wild-type or XLID
mutant CUL4B by homologous recombination [28]. Brieﬂy, cDNA of
wild-type, (R572C), (V745A) or (R388X) CUL4B was subcloned into
pShuttle-CMV vector provided in the kit. The resulting plasmid was
cotransformed into Escherichia coli. BJ5183 cells with adenoviral back-
bone plasmid pAdEasy-1. Recombinant adenoviral plasmid was then
transfected into HEK 293 cells. Following the ampliﬁcation in HEK 293
cells, viral stocks were puriﬁed by CsCl gradient ultracentrifugation.
Twenty-four hours after plating, cultured neocortical neurons were
infected with recombinant adenoviruses.2.5. Infection of recombinant lentiviruses containing shRNA of CUL4B
Lentiviral vector pLKO.1 containing short hairpin RNA (shRNA)
targetingmouse CUL4B (clone ID, TRCN0000012791; target sequence,
5′-CCACGTACCTATACAGAA-3′) was obtained from National RNAi
Core Facility at the Academia Sinica and used for preparation of re-
combinant lentiviruses. One day after plating, cultured neocortical
neurons were infected with recombinant lentiviruses containing
shRNA of CUL4B.
Fig. 1. Stable expression of HA-tagged wild-type or XLID mutant CUL4B in HEK 293
cells. Following the stable transfection of cDNA encoding HA-tagged wild-type or
XLID mutant CUL4B, immunoblotting assays using anti-HA antibody indicated that
wild-type, (R572C) or (V745A) CUL4B (M.W.=~110 kDa) was stably expressed in
HEK 293 cells. Molecular weight of C-terminal truncated (R388X) CUL4B expressed
in 293 cells was reduced to ~41 kDa.
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HEK293 cells expressing CUL4B
HEK293 cells stably expressing wild-type or XLID mutant CUL4B
were homogenized and solubilized with ice-cold lysis buffer containing
150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 50 mM
Tris–HCl (pH7.4), 1 mM EDTA, 5 μg/ml pepstain, 5 μg/ml leupetin,
5 μg/ml aprotinin, and 0.3 mM PMSF. Following the centrifugation at
15,000 g for 20 min at 4 °C, the supernatant (1 mgprotein)was incubat-
ed with 50 μl of protein A-agarose suspension for 3 h at 4 °C. After the
centrifugation, the supernatant was incubated with 1 μg of monoclonal
anti-FK-2 antibody against polyubiquitinated and monoubiquitinated
proteins (Enzo Life Sciences) and 50 μl of protein A-agarose suspension
overnight at 4 °C. Following the centrifugation at 4 °C, the beads were
washed three times with lysis buffer. Subsequently, SDS-PAGE sample
buffer was added to the beads, and the sample was heated at 95 °C for
5 min. The supernatant containing the immunocomplex was obtained
after the centrifugation and resolved on SDS-polyacrylamide gel. Then,
immunoblotting assay with anti-TSC2 polyclonal antibody, monoclonal
anti-cyclin E antiserum or polyclonal anti-TSC1 antibody was performed
as described below.
2.7. Western blot analysis
Protein samples were prepared by homogenizing cultured neocorti-
cal neurons infected with adenoviruses or lentiviruses and HEK 293
cells stably expressing wild-type or mutant CUL4B with SDS sample
buffer. Subsequently, protein lysate or the immunocomplex was frac-
tionated on 8 or 10% SDS-polyacrylamide gel and transferred to PVDF
membrane. Then, the membrane was incubated at 4 °C overnight
with one of the following diluted primary antibodies: (1) Anti-HA
monoclonal antiserum (Cell Signalling Technology). (2) Polyclonal
anti-CUL4B antibody (Sigma). (3) Anti-mTOR polyclonal antibody
(Cell Signaling Technology). (4) Polyclonal anti-phospo-mTORSer2448
antiserum (Cell Signalling Technology). (5) Anti-p70S6K polyclonal an-
tibody (Cell Signaling Technology). (6) Polyclonal Anti-phospho-
p70S6KThr389 antiserum (Cell Signaling Technology). (7) Anti-4E-BP1
polyclonal antibody (Cell Signaling Technology). (8) Polyclonal
anti-phospho-4E-BP1Thr37/46 antiserum (Cell Signalling Technology).
(9) Anti-TSC2 polyclonal antiserum (Santa Cruz). (10) Monoclonal
anti-cyclin E antibody (Santa Cruz). (11) Anti-TSC1 polyclonal antise-
rum (Epitomics). After being washed, the membrane was incubated
with horse anti-mouse or donkey anti-rabbit horseradish peroxidase-
linked secondary antibody. Then, immunoreactive proteins were
visualized by using enhanced chemiluminescence kit (GE Biosciences).
To conﬁrm the equal amount of protein samples loaded, membrane
was stripped and reblotted with monoclonal anti-actin antibody
(Chemicon). Gel bands were quantiﬁed with the aid of densitometer
(Molecular Dynamics Model 375A) and normalized with reprobed
actin signal on the same blot.
2.8. Statistical analysis
All results are expressed as the mean±S. E. value of n experiments.
Statistical signiﬁcance among multiple experimental groups is deter-
mined by one-way ANOVA followed by Dunnett's test. Unpaired stu-
dent's t-test (two-tailed) is used to determine the signiﬁcant difference
between two groups of data. A p valueb0.05 is considered signiﬁcant.
3. Results
3.1. XLID CUL4B mutants fail to promote ubiquitylation and degradation
of TSC2 and cyclin E in HEK 293 cells
(R572C), (V745A) or truncated (R388X) CUL4B mutation was
found in male XLID patients [6,7]. Therefore, we prepared cDNAencoding mutant (R572C), (V745A) or C-terminal truncated (R388X)
human CUL4B. To characterizewild-type or XLID CUL4B using immuno-
blotting assay, inﬂuenza hemagglutinin epitope (HA) was added to the
C-terminus of wild-type or mutant CUL4B protein. Then, we investigat-
ed the functional consequence of XLID mutation by stably expressing
wild-type or XLID mutant CUL4B in HEK 293 cells. Western blotting
analysis using anti-HA antiserum showed that similar to HA-tagged
wild-type CUL4B, 293 cells stably transfected with the cDNA of
HA-tagged (R572C) or (V745A) CUL4B expressed a high level of
~110 kDa-immunoreactive protein (Fig. 1). As expected, molecular
weight of HA-tagged truncated (R388X) CUL4B expressed was reduced
to ~41 kDa (Fig. 1).
In the present study, we hypothesized that XLID mutations impair
the activity of CUL4B-RING E3 ubiquitin ligase and that XLID CUL4B
mutants fail to promote the degradation of protein substrates. In ac-
cordance with s previous study showing that wild-type CUL4B in
HEK 293 cells promoted the degradation of TSC2 [25], our Western
blot analysis showed that protein expression of TSC2 was signiﬁcantly
downregulated in HEK 293 cells stably expressing wild-type CUL4B
(Fig. 2A). On the other hand, XLMR mutant (R388X), (R572C) or
(V745A) CUL4B overexpressed in 293 cells failed to signiﬁcantly de-
crease the protein level of TSC2 (Fig. 2A).
In addition to TSC2, wild-type CUL4B-RING E3 ligase has also been
shown to enhance the degradation of cyclin E in HEK 293 cells [29,30].
To further conﬁrmour hypothesis that XLID truncating ormissensemu-
tations impair the abilityof CUL4B to promote degradation of protein
substrates, we also visualized protein level of cyclin E in 293 cells stably
expressing wild-type or XLID mutant CUL4B. Immunoblotting assays
showed that protein level of cyclin E was signiﬁcantly decreased in
293 cells expressing wild-type CUL4B (Fig. 2B). In contrast, compared
to control HEK 293 cells, protein expression of cyclin E was not altered
in 293 cells stably transfected with cDNA of mutant (R388X), (R572C)
or (V745A) CUL4B (Fig. 2B).
Overexpression of wild-type CUL4B decreased protein level of TSC2
or cyclin E in HEK293 cells, indicating that wild-type CULB promotes
degradation of TSC2 or cyclin E by ubiquitinating TSC2 or cyclin E. In
contrast to wild-type CUL4B, stable expression of XLID mutant
(R388X), (R572C) or (V745A) CUL4B did not affect the protein level of
TSC2 or cyclin E in HEK293 cells, suggesting that XLID mutant CUL4B
failed to promote ubiquitylation of TSC2 or cyclin E. To prove this hy-
pothesis, an equal amount of solubilized cellular extract prepared
from control HEK293 cells or 293 cells overexpressing wild-type or
XLID mutant CUL4B was immunoprecipitated with monoclonal anti-
Fig. 2. XLID CUL4B mutants fail to downregulate protein expression of TSC2 or cyclin E in HEK293 cells. (A) Immunoblotting assays showed that compared to control cells, protein
level of TSC2 was signiﬁcantly reduced in HEK293 cells stably expressing wild-type CUL4B. In contrast to wild-type CUL4B, XLID mutant (R388X), (R572C) or (V745A) CUL4B did
not signiﬁcantly decrease TSC2 protein level. (B) Western blot analysis indicated that protein expression of cyclin E was signiﬁcantly downregulated in 293 cells expressing
wild-type CUL4B. Note that protein level of cyclin E was not signiﬁcantly altered in HEK 293 cells stably expressing XLID mutant (R388X), (R572C) or (V745A) CUL4B. Each bar
represents the mean±S. E. value of 6–7 experiments. *Pb0.01 compared to control cells (one-way ANOVA followed by Dunnett's test).
588 H.-L. Wang et al. / Biochimica et Biophysica Acta 1832 (2013) 585–593FK-2 antiserum that recognizes ubiquitinated proteins, and then immu-
noprecipitates were analyzed byWestern blot assay with anti-TSC2 an-
tibody. Compared to control 293 cells, stable expression of wild-type
CUL4B signiﬁcantly increased the protein level of high-molecular-
mass polyubiquitinated TSC2 (Fig. 3A). In contrast, XLID mutant
(R388X), (R572C) or (V745A) CUL4B failed to signiﬁcantly promote
ubiquitylation of TSC2 (Fig. 3A). Immunoprecipitation using anti-FK-2
antibody and subsequent immunoblotting assay of immunocomplexFig. 3. XLID CUL4B mutants are defective in promoting ubiquitylation of TSC2 or cyclin E. (A)
wild-type or XLID mutant CUL4B was immunoprecipitated with anti-FK-2 antibody, which
using anti-TSC2 antiserum. Note that ubiquitylation of TSC2 was greatly enhanced in HEK29
did not signiﬁcantly promote TSC2 polyubiquitination. (B) Solubilized cellular extract was i
using anti-cyclin E antiserum. Wild-type CUL4B signiﬁcantly increased ubiquitylation of cy
ubiquitination of cyclin E. (C) Immunoprecipitating cellular extract with anti-FK-2 antib
wild-type or XLID CUL4B mutants did not promote ubiquitylation of TSC1. Each bar shows
ANOVA followed by Dunnett's test).using anti-cyclin E antiserum also demonstrated that compared to con-
trol non-transfected 293 cells, overexpression of wild-type CUL4B pro-
moted ubiquitination of cyclin E (Fig. 3B). On the other hand, XLID
mutant (R388X), (R572C) or (V745A) CUL4B did not augment
ubiquitylation of cyclin E (Fig. 3B). As a control, immunoprecipitation
using anti-FK-2 antibody and subsequent Western blot assay using
anti-TSC1 antiserum showed that neither wild-type CUL4B nor XLID
CUL4B mutants enhanced ubiquitination of TSC1 (Fig. 3C).The same amount of solubilized cellular extract prepared from HEK293 cells expressing
recognizes ubiquitinated proteins, and visualized by subsequent immunoblotting assay
3 cells expressing wild-type CUL4B. XLID mutant (R388X), (R572C) or (V745A) CUL4B
mmunoprecipitated by ant-FK-2 antibody and then visualized by Western blot analysis
clin E. In contrast, XLID mutant (R388X), (R572C) or (V745A) CUL4B failed to enhance
ody and subsequent immunoblotting assay using anit-TSC1 antiserum showed that
the mean±S. E. value of 5 experiments. *Pb0.01 compared to control cells (one-way
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expression of TSC2 or cyclin E in neocortical neurons of frontal lobe
In the previous sections, our results indicated that XLID CUL4B
mutants were defective in promoting the degradation of TSC2 and
cyclin E in HEK 293 cells. XLID mutant CUL4B is believed to cause
dysregulated neuronal function or development in the frontal lobe
of cerebral cortex and resulting intellectual disability [31–34]. In the
present study, we hypothesized that CUL4B positively regulates
mTOR signaling of frontal cortex by promoting the removal of TSC2,
a negative regulator of mTOR activity, and that XLID CUL4B mutants
lose the ability to cause the degradation of TSC2, leading to the
dysregulated mTOR signaling in neocortical neurons of frontal lobe.
Thus, it is essential to show that XLID mutations cause the loss of
CULB-mediated downregulation of TSC2 protein expression in neo-
cortical neurons of frontal cortex.
To express wild-type or XLID mutant CUL4B in cultured neocorti-
cal neurons of mouse frontal lobe, we prepared recombinant adenovi-
ruses containing the cDNA of HA-tagged wild-type, (R388X), (R572C)
or (V745A) CUL4B. Three days after the infection with adenoviruses
containing the cDNA of wild-type or XLID mutant CUL4B, Western
blot study showed that HA-tagged wild-type, (R572C), (V745A) or
(R388X) CUL4B was highly expressed in cultured neocortical neurons
of frontal cortex (Fig. 4). Consistent with the results observed in 293
cells, immunoblotting study showed that three days after infecting
adenoviruses containing the cDNA of wild-type CUL4B, protein level
of TSC2 was greatly reduced in neocortical neurons of frontal lobe
(Fig. 5A). In contrast, protein expression of TSC2 was not signiﬁcantly
altered in neocortical neurons expressing XLID mutant (R388X),
(R572C) or (V745A) CUL4B (Fig. 5A).
Similar to the ﬁnding observed in 293 cells, Western blot assays indi-
cated that overexpression of wild-type CUL4B in neocortical neurons of
frontal cortex also decreased protein level of cyclin E (Fig. 5B). On the
other hand, three days after the infection of adenoviruses containing
cDNA of XLID mutant (R388X), (R572C) or (V745A) CUL4B, a similar
protein level of cyclin Ewas detected in cultured neocortical neurons ex-
pressing XLID mutant CUL4B and control non-infected neurons (Fig. 5B).
3.3. Knockdown of CUL4B upregulates protein level of TSC2 or cyclin E in
cultured neocortical neurons
If CUL4B promotes the degradation of TSC2 or cyclin E and acts as a
physiological regulator of TSC2 or cyclin E protein expression inFig. 4. Recombinant adenoviruses-mediated expression of wild-type or XLID mutant
CUL4B in neocortical neurons of frontal lobe. Three days after the infection with re-
combinant adenoviruses containing the cDNA of HA-tagged wild-type or XLID mutant
CUL4B, immunoblotting assays using anti-HA antibody showed that HA-tagged
wild-type, (R572C) or (V745A) or C-terminal truncated (R388X)CUL4B was highly
expressed in cultured neocortical neurons of frontal cortex.neocortical neurons of frontal cortex, shRNA-mediated knockdown
of CUL4B expression is expected to cause the accumulation of TSC2
or cyclin E in neocortical neurons. Three days after infecting cultured
neocortical neurons with lentiviruses containing shRNA targeting
CUL4B, about 90% of CUL4B protein expression was suppressed
(Figs. 6 and 7). Infection of lentiviruses containing control scrambled
shRNA did not affect protein level of CUL4B (data not shown). shRNA-
mediated knockdown of CUL4B protein level greatly upregulated pro-
tein expression of cyclin E (Fig. 6) or TSC2 (Fig. 7) in cultured neocorti-
cal neurons.
3.4. XLID CUL4B mutants fail to positively regulate mTOR activity in
neocortical neurons
Knockdown of CUL4B-induced upregulation of TSC2 in neocortical
neurons of frontal lobe led to a decrease in protein level of active
phospho-mTORSer2448 (Fig. 7) by inhibiting the activity of Rheb
GTPase, a positive regulator of mTOR signaling, Then, reduced level
of phospho-mTORSer2448 caused an impaired phosphorylation and
activation of p70S6KThr389 and 4E-BP1Thr37/46 (Fig. 7), two main effec-
tors of mTORC1 signaling cascade. These results show that wild-type
CUL4B positively regulates mTOR activity and is required for normal
mTORC1 signaling pathway in neocortical neurons of frontal cortex.
In accordance with our hypothesis that CUL4B acts as a positive reg-
ulator of mTOR activity, overexpression of wild-type CUL4B augmented
mTORC1 pathway activity of cultured neocortical neurons by signiﬁcant-
ly upregulating protein expression of active phospho-mTORSer2448,
phospho-p70S6KThr389 or phospho-4E-BP1Thr37/46 (Fig. 8). In contrast,
infecting neocortical neurons with adenoviruses containing the cDNA
of XLID mutant (R388X), (R572C) or (V745A) CUL4B failed to increase
protein level of phospho-mTORSer2448, phospho-p70S6KThr389 or
phospho-4E-BP1Thr37/46 (Fig. 8).
4. Discussion
Molecular genetic studies reported that truncating or missense mu-
tations, including (R388X), (R572C) and (V745A) mutations, of cullin
4B (CUL4B) gene located on the Xq24 locus were observed in male pa-
tients with intellectual disability [6,7]. CUL4B mutation is one of the
most common mutated genes causing X-linked intellectual disability
(XLID) [6–10]. Better understanding of the functional consequence of
XLID mutations on CUL4B-mediated physiological effects and possible
pathogenic mechanism underlying mutant CUL4B-induced cognitive
impairment is essential for the development of therapeutic strategy
for mutant CUL4B-induced XLID.
Previous studies using HEK 293 cell line showed that TSC2 and
cyclin E are protein substrates of CUL4B–RING E3 ligase-mediated
ubiquitylation and degradation [25,29,30]. We hypothesized that XLID
CUL4B mutants are defective in mediating ubiquitylation and degrada-
tion of protein substrates in the brain, which results in intellectual dis-
ability [6,7]. Our study showed that stable expression of wild-type
CUL4B signiﬁcantly decreased protein level of TSC2 or cyclin E in 293
cells. In contrast, XLMRmutant (R388X), (R572C) or (V745A) CUL4B sta-
bly expressed in HEK 293 cells did not downregulate the protein expres-
sion of TSC2 or cyclin E. In the present study, immunoprecipitation using
anti-FK-2 antibody, which recognizes polyubiquitinated proteins, com-
bined with subsequent Western blot analysis of immunocomplex using
anti-TSC2 or anti-cyclin E antiserum indicated that overexpression of
wild-type CUL4B augmented ubiquitylation of TSC2 or cyclin E in 293
cells. On the contrary, XLID mutant (R388X), (R572C) or (V745A)
CUL4B failed to promote ubiquitination of TSC2 or cyclin E. Our results
provide the evidence that XLID mutations cause the loss of CUL4B
function and that XLID mutant (R388X), (R572C) or (V745A) CUL4B
is defective in promoting ubiquitylation and degradation of TSC2 or
cyclin E. XLID mutant (R388X) CUL4B lacks the C-terminal domain,
and the location of XLID (R572C) or (V745A) mutation is close to the
Fig. 5. XLID CUL4B mutants fail to downregulate protein expression of TSC2 or cyclin E in neocortical neurons of frontal lobe. (A) Three days after infecting cultured neocortical
neurons with adenoviruses containing cDNA of wild-type or XLID mutant CUL4B, Western blot analysis demonstrated that compared to control non-infected neurons, protein ex-
pression of TSC2 was signiﬁcantly downregulated in neocortical neurons expressing wild-type CUL4B. In contrast, XLID mutant (R388X), (R572C) or (V745A) CUL4B did not sig-
niﬁcantly alter protein level of TSC2. (B) Immunoblotting assays showed that protein level of cyclin E was signiﬁcantly decreased in cultured neocortical neurons expressing
wild-type CUL4B. On the other hand, XLID mutant (R388X), (R572C) or (V745A) CUL4B failed to affect protein expression of cyclin E. Each bar represents the mean±S. E. value
of 6–7 experiments. *Pb0.01 compared to control non-infected neocortical neurons (one-way ANOVA followed by Dunnett's test).
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(R572C) or (V745A) CUL4B mutation impairs the binding between the
C-terminal domain of CUL4B and RING protein ROC1 or ROC2, which
prevents the formation of functional CUL4B-RING E3 ubiquitin ligase.
The mTOR signaling pathway plays an important role in regulating
dendritic arborization during the neuronal development [14,17]. Acti-
vation of mTOR signaling pathway is functionally linked with local
protein synthesis within synapses, leading to the production of pro-
teins required for the formation and maturation of new spines
[14,15]. Two phenomena of synaptic plasticity in glutamatergic trans-
mission, late long-term potentiation (LTP) or mGluR-dependent
long-term depression (mGluR-LTD), are believed to be cellular sub-
strates for learning and memory [18–21]. Proper translational control
via mTOR signaling cascade is required for normal expression of
late-LTP and mGluR-LTD [18–20,22,23]. Thus, dysregulation of
mTOR signaling activity in the cerebral cortex, which causes an im-
paired late-LTP or mGluR-LTD and an aberrant dendrite development
or spine morphogenesis, could be one of molecular pathogenic mech-
anisms underlying intellectual disability [21].Fig. 6. shRNA-mediated knockdown of CUL4B expression increases protein level of cycli
containing shRNA targeting CUL4B greatly decreased protein level of CUL4B. Knockdown of
E in cultured neocortical neurons of frontal cortex. Each bar shows the mean±S. E. value oXLID is likely to result from dysregulated neuronal function or de-
velopment in several regions of brain including frontal lobe [31–34].
Therefore, we investigated wild-type or XLID mutant CUL4B modula-
tion of TSC2 or cyclin E protein expression in the neocortical neurons
of frontal cortex. Recombinant adenoviruses-mediated expression
of wild-type CUL4B signiﬁcantly decreased protein level of TSC2 or
cyclin E in cultured neocortical neurons of frontal lobe. Furthermore,
shRNA-mediated knockdown of CUL4B expression led to a signiﬁcant
upregulation of TSC2 or cyclin E protein level, suggesting that CUL4B
promotes the degradation of TSC2 or cyclin E and acts as a physiological
regulator of TSC2 or cyclin E protein expression in neocortical neurons
of frontal cortex. In contrast to wild-type CUL4B, overexpression
of XLID mutant (R388X), (R572C) or (V745A) CUL4B failed to
downregulate protein expression of TSC2 or cyclin E in cultured neocor-
tical neurons. Therefore, XLID CUL4B mutants are defective in enhanc-
ing the degradation of TSC2 or cyclin E in neocortical neurons of
frontal lobe.
TSC2 negatively regulates mTOR activity by inhibiting the Rheb
GTPase, a positive regulator of mTORC1 signaling cascade [14,15].n E in cultured neocortical neurons. Infecting neocortical neurons with lentiviruses
CUL4B expression was accompanied by a signiﬁcant increase in protein level of cyclin
f 6 experiments. *Pb0.01 compared to control non-infected neurons.
Fig. 7. CUL4B positively regulates the mTOR activity by promoting TSC2 degradation in neocortical neurons of frontal lobe. Three days after infecting cultured neocortical neurons
with lentiviruses containing shRNA targeting CUL4B, Western blot analysis indicated a pronounced decrease in CUL4B protein expression, leading to a signiﬁcant increase in protein
level of TSC2. Upregulation of TSC2 expression caused by knockdown of CUL4B resulted in an impairment of mTORC1 signaling pathway, which was indicated by a decreased pro-
tein expression of active phospho-mTORSer2448, phospho-p70S6KThr389or phospho-4E-BP1Thr37/46 in neocortical neurons of frontal cortex. Each bar represents the mean±S. E. value
of 6 experiments. *Pb0.05 compared to control non-infected neocortical neurons. **Pb0.01 compared to control non-infected neurons.
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of mTOR activity was indicated by a previous study showing that het-
erozygous Tsc2+/− knockout mice displayed the disinhibition of
mTOR signaling activity in the brain, which led to a lower threshold
for the induction of late long-term potentiation [35]. By causing
ubiquitination and promoting degradation of TSC2, CUL4B could
play a critical role in regulating the mTOR activity in the neocortical
neurons of frontal cortex. Consistent with this hypothesis, knock-
down of CUL4B-induced upregulation of TSC2 in neocortical neurons
of frontal lobe resulted in a decrease in protein level of active
phospho-mTORSer2448 and a reduced level of active p70S6KThr389Fig. 8. XLID CUL4B mutants fail to positively regulate mTOR signaling in neocortical neurons o
wild-type CUL4Bpromoted the activation and phosphorylation ofmTORSer2448. Overexpression
ofmTORSer2448. (B)Western blot study showed that protein expression of active phospho-p70S
In contrast, XLID CUL4B mutants did not increase protein level of phospho-p70S6KThr389. (C)W
sion of active phospho-4E-BP1Thr37/46. XLID mutant (R388X), (R572C) or (V745A) failed to sig
value of 6 experiments. *Pb0.01 compared to control non-infected neocortical neurons (one-wand 4E-BP1Thr37/46, two main protein substrates of mTOR-mediated
phosphorylation. Overexpression of wild-type CUL4B also signiﬁcant-
ly enhanced mTORC1 pathway activity of neocortical neurons by
increasing protein level of active phospho-mTORSer2448, phospho-
p70S6KThr389 or phospho-4E-BP1Thr37/46. Our results provide the evi-
dence that CUL4B positively regulates mTOR activity and is required
for normal mTORC1 signaling pathway in neocortical neurons of fron-
tal cortex. In contrast to wild-type CUL4B, recombinant adenoviruses-
mediated expression of XLID mutant (R388X), (R572C) or (V745A)
CUL4B did not affect protein level of active phospho-mTORSer2448,
phospho-p70S6KThr389 or phospho-4E-BP1Thr37/46 in cultured neocorticalf frontal cortex. (A) Infecting neocortical neurons with adenoviruses containing cDNA of
of XLIDmutant (R388X), (R572C) or (V745A) CUL4B failed to enhance the phosphorylation
6KThr389 was signiﬁcantly upregulated in neocortical neurons expressingwild-type CUL4B.
ild-type CUL4B expressed in neocortical neurons signiﬁcantly upregulated protein expres-
niﬁcantly affect protein level of phospho-4E-BP1Thr37/46. Each bar shows the mean±S. E.
ay ANOVA followed by Dunnett's test).
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in positively regulating mTOR activity in neocortical neurons of frontal
lobe.
Our results suggest that one of CUL4B-mediated physiological func-
tions in neocortical neurons of frontal lobe is to promote TSC2 degrada-
tion and enhancemTOR signaling activity. On the contrary, XLIDmutant
(R388X), (R572C) or (V745A) CUL4B is defective in promoting degrada-
tion of TSC2 and augmenting mTOR signaling cascade in neocortical
neurons of frontal lobe. Therefore, one of the possible pathogenic
mechanisms underlying XLID mutant (R388X), (R572C) or (V745A)
CUL4B-inducedmale patient's cognitive dysfunctionmay be the impair-
ment of XLID CUL4B mutant-mediated degradation of TSC2 and subse-
quent accumulation of TSC2, leading to downregulation of mTORC1
pathway activity and impaired neuronal development and long-term
synaptic plasticity.
Cyclin E is a component of the core cell cycle machinery and is
highly expressed in proliferating cells. A high level of cyclin E is also
found in the postmitotic neurons in the nervous system [36–38].
Our study shows that overexpression of wild-type CUL4B in neocorti-
cal neurons of frontal cortex decreased protein level of cyclin E.
Furthermore, protein expression of cyclin E was upregulated in cul-
tured neocortical neurons infected with shRNA of CUL4B. Consistent
with our hypothesis that XLID mutations cause the loss of CUL4 B
function, XLID mutant (R388X), (R572C) or (V745A) CUL4B failed to
alter protein level of cyclin E in cultured neocortical neurons. Abnor-
mal elevation of pro-apoptotic cyclin E level has been shown to cause
apoptotic cell death of cerebellar granule neurons, midbrain dopami-
nergic neurons and neocortical neurons [35–37]. A recent study also
reported that cyclin E forms complexes with cyclin-dependent kinase
5 and regulates synaptic plasticity and memory formation through
controlling the number of synapses and dendritic spines [39]. There-
fore, wild-type CUL4B is likely to exert a neuroprotective effect on
neocortical cells and modulate synaptic and memory function of neo-
cortical neurons of frontal lobe by negatively regulating protein level
of cyclin E. In contrast, XLID mutant (R388X), (R572C) or (V745A)
CUL4B exhibited an impaired ability to promote the degradation of
cyclin E, suggesting that XLID CUL4B mutants lose the ability of
protecting neocortical neurons and regulating synaptic plasticity
and memory formation in the frontal cortex via downregulating pro-
tein expression of cyclin E.
In the present study, our shRNA-mediated knockdown experi-
ments suggest that CUL4B functions as a physiological regulator of
TSC2 or cyclin E protein expression in neocortical neurons of frontal
cortex. Recently, CUL4B knockout mice were also prepared to study
physiological functions of CUL4B and possible pathogenic mechanism
of XLID CUL4B mutant-induced cognitive impairment [26,40]. Embry-
onic lethality with pronounced growth inhibition and increased apo-
ptosis in extra-embryonic tissues were observed in CUL4B knockout
mice, indicating that CUL4B plays an essential developmental role in
the extra-embryonic tissues [40]. Interestingly, the deﬁciency of
CUL4B in the hippocampus led to the reduced dendritic arborization
and impaired spatial memory function of rescued conditional CUL4B
knockout mice [26]. This ﬁnding raises the possibility that loss of
CUL4B causes the accumulation of TSC2 and diminished mTOR signal-
ing activity, resulting in an impaired dendritic development and
memory function of the hippocampus [26].
In addition to TSC2 and cyclin E studied in the present study,
CUL4B–RING E3 ubiquitin ligase also promotes ubiquitination and
degradation of β-cantenin, androgen receptor, estrogen receptor
and peroxiredoxin III [41–43]. Wnt/β-cantenin signaling pathway is
involved in proper neuronal development and function of the CNS
[44]. Androgen and estrogen receptors regulate synaptic function
and synaptic plasticity in the brain [45,46]. Peroxiredoxin III could
affect neural development through regulating the reactive oxygen
species (ROS) level [43,47]. Further study is required to determine
whether XLID mutant (R388X), (R572C) or (V745A) CUL4B is alsodefective in promoting the degradation of β-cantenin, androgen re-
ceptor, estrogen receptor or peroxiredoxin III, resulting in impaired
neuronal development and synaptic plasticity.
In summary, the present study provides the evidence that
wild-type CUL4B positively regulates the mTOR activity and exerts a
neuroprotective effect in the neocortical neurons of frontal cortex
by promoting degradation of TSC2 and cyclin E, respectively. In con-
trast to wild-type CUL4B, XLID (R388X), (R572C) and (V745A)
CUL4B mutants are defective in downregulating protein expression
of TSC2 or cyclin E in the neocortical neurons of frontal lobe. The
mTOR signaling cascade is required for neuronal development,
long-term synaptic plasticity and cognitive function in the cerebral
cortex [14,15,18–21]. Our results suggest that XLID (R388X),
(R572C) and (V745A) mutations impair CUL4B-mediated degrada-
tion of TSC2 and cause resulting accumulation of TSC2 and inhibition
of mTOR activity, leading to the malfunction of frontal cortex and in-
tellectual disability.Acknowledgement
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